Michael Hodges
Consultant / Advisor chez EFFECTOR THERAPEUTICS, INC.
Profil
Michael R Hodges is currently the Chief Executive Officer at 1Strand.
He is also a Partner at Claris Ventures Sgr SpA, a Senior Advisor at Adjuvant Capital LP, an Advisor at eFFECTOR Therapeutics, Inc., and a Board Member at Resalis Therapeutics SRL.
In his former positions, Mr. Hodges served as a Non-Executive Director at F2G Ltd., a Principal at Pfizer Inc., the Chief Medical Officer at Kémia, Inc., the Chief Medical Officer & Vice President at Roche Innovation Center Copenhagen A, and a Principal at Kent County Memorial Hospital.
He also held the role of Chief Medical Officer at Altair Therapeutics, Inc. from 2009 to 2011, and at Amplyx Pharmaceuticals, Inc. from 2016 to 2021.
Additionally, he was a Principal at St. Thomas Hospital, Inc. in 1990 and a Senior Medical Advisor at the US Air Force from 2018 to 2021.
He served as an Advisor at Arcturus Therapeutics Holdings, Inc.Mr. Hodges completed his undergraduate and graduate degrees at East Carolina University in 1993.
He also pursued undergraduate and doctorate degrees at the University of London, an undergraduate degree at The King's College (New York), and a graduate degree at Wright State University (Ohio).
He obtained his doctorate degree from Brody School of Medicine in 1999.
Postes actifs de Michael Hodges
| Sociétés | Poste | Début |
|---|---|---|
| EFFECTOR THERAPEUTICS, INC. | Consultant / Advisor | - |
Adjuvant Capital LP
 Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | Consultant / Advisor | - |
Resalis Therapeutics SRL
 Resalis Therapeutics SRL Miscellaneous Commercial ServicesCommercial Services Resalis Therapeutics SRL is a company that focuses on developing a transformative metabolic disease approach to target obesity and fatty liver disease. The company is based in Turin, Italy. The Italian company's lead program, RES-010, is a safe and convenient treatment that provides disease-modifying therapeutic impact, including durable weight loss and reduction of hepatic steatosis. The CEO of the company is Eva Castagnetti. | Directeur/Membre du Conseil | 01/01/2021 |
Claris Ventures Sgr SpA
 Claris Ventures Sgr SpA Investment ManagersFinance Claris Ventures Sgr SpA (Claris Ventures) is a venture capital firm founded in 2019 by Pietro Puglisi and Ciro Spedaliere. The firm is headquartered in Turin, Italy. | Private Equity Investor | 01/01/2023 |
Anciens postes connus de Michael Hodges
| Sociétés | Poste | Fin |
|---|---|---|
| US Air Force | Consultant / Advisor | 30/06/2021 |
Amplyx Pharmaceuticals, Inc.
 Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | Directeur Technique/Scientifique/R&D | 01/06/2021 |
Altair Therapeutics, Inc.
 Altair Therapeutics, Inc. Medical DistributorsDistribution Services Altair is a privately owned company that was spun out of ISIS Pharmaceuticals in October 2007 with the objective of applying ISIS’s proprietary second generation (2’-MOE Gapmer) antisense oligoneucleotide technology to the field of inhaled therapeutics. Through its collaboration with ISIS Altair has access to both near term clinical stage opportunities, as well as early stage development projects. Altair's first compound AIR645 is currently in phase I clinical trials. This first in class compound posses unique anti-inflammatory activities appropriate for multiple therapeutic applications, including asthma, rhinitis and COPD. Additionally, the characteristics of the 2'-MOE Gapmer chemistry provides for the possibility of administration of AIR645 as an inhaled therapeutic delivered once weekly. Altair is also planning on developing a future pipeline of other best-in-class molecules for respiratory targets by exploiting the advantages of its propriety 2nd generation antisense oligonucleotide chemistry. | Directeur Technique/Scientifique/R&D | 09/03/2011 |
Kent County Memorial Hospital
 Kent County Memorial Hospital Hospital/Nursing ManagementHealth Services Kent County Memorial Hospital provides health care services. It also provides inpatient services including cardiology and extended coronary care, infectious disease, primary care, oncology, orthopedics, obstetrics and gynecology, pediatrics, rehabilitation and surgery. The company was founded in 1951 and is headquartered in Warwick, RI. | Corporate Officer/Principal | 01/01/2001 |
St. Thomas Hospital, Inc.
 St. Thomas Hospital, Inc. Hospital/Nursing ManagementHealth Services St. Thomas Hospital, Inc. operates hospitals. The private company is based in St. Thomas, VI. and has subsidiaries in United States. | Corporate Officer/Principal | 01/01/1990 |
Formation de Michael Hodges
| University of London | Doctorate Degree |
| Brody School of Medicine | Doctorate Degree |
| East Carolina University | Graduate Degree |
| Wright State University (Ohio) | Graduate Degree |
| The King's College (New York) | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ARCTURUS THERAPEUTICS HOLDINGS INC. | Health Technology |
| EFFECTOR THERAPEUTICS, INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| Entreprise privées | 11 |
|---|---|
Adjuvant Capital LP
Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | Finance |
| US Air Force | Government |
Kémia, Inc.
 Kémia, Inc. Pharmaceuticals: MajorHealth Technology Kémia, Inc. discovered and developed novel small molecule therapeutics for inflammation, cancer, HIV, diabetes and bone diseases. The firm specialized in the fields of medicinal and analytical chemistry, biology, pharmacology, pharmacokinetics, pharmacodynamics, and clinical development. The company was founded in 2002 and was headquartered in San Diego, CA. | Health Technology |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Health Technology |
Kent County Memorial Hospital
Kent County Memorial Hospital Hospital/Nursing ManagementHealth Services Kent County Memorial Hospital provides health care services. It also provides inpatient services including cardiology and extended coronary care, infectious disease, primary care, oncology, orthopedics, obstetrics and gynecology, pediatrics, rehabilitation and surgery. The company was founded in 1951 and is headquartered in Warwick, RI. | Health Services |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Health Technology |
Altair Therapeutics, Inc.
Altair Therapeutics, Inc. Medical DistributorsDistribution Services Altair is a privately owned company that was spun out of ISIS Pharmaceuticals in October 2007 with the objective of applying ISIS’s proprietary second generation (2’-MOE Gapmer) antisense oligoneucleotide technology to the field of inhaled therapeutics. Through its collaboration with ISIS Altair has access to both near term clinical stage opportunities, as well as early stage development projects. Altair's first compound AIR645 is currently in phase I clinical trials. This first in class compound posses unique anti-inflammatory activities appropriate for multiple therapeutic applications, including asthma, rhinitis and COPD. Additionally, the characteristics of the 2'-MOE Gapmer chemistry provides for the possibility of administration of AIR645 as an inhaled therapeutic delivered once weekly. Altair is also planning on developing a future pipeline of other best-in-class molecules for respiratory targets by exploiting the advantages of its propriety 2nd generation antisense oligonucleotide chemistry. | Distribution Services |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | Health Technology |
St. Thomas Hospital, Inc.
St. Thomas Hospital, Inc. Hospital/Nursing ManagementHealth Services St. Thomas Hospital, Inc. operates hospitals. The private company is based in St. Thomas, VI. and has subsidiaries in United States. | Health Services |
Claris Ventures Sgr SpA
Claris Ventures Sgr SpA Investment ManagersFinance Claris Ventures Sgr SpA (Claris Ventures) is a venture capital firm founded in 2019 by Pietro Puglisi and Ciro Spedaliere. The firm is headquartered in Turin, Italy. | Finance |
Resalis Therapeutics SRL
Resalis Therapeutics SRL Miscellaneous Commercial ServicesCommercial Services Resalis Therapeutics SRL is a company that focuses on developing a transformative metabolic disease approach to target obesity and fatty liver disease. The company is based in Turin, Italy. The Italian company's lead program, RES-010, is a safe and convenient treatment that provides disease-modifying therapeutic impact, including durable weight loss and reduction of hepatic steatosis. The CEO of the company is Eva Castagnetti. | Commercial Services |
